Once enrolled in the trial, participants will be randomly allocated to either the placebo or active group (60 people per group). Satiety, dietary intake, body composition and tolerance will be assessed at enrolment. Within the week pre-treatment, participant’s blood will be collected for analysis of pre-treatment blood markers. All participants will receive the same standard advice regarding diet and physical activity.
Participants will be asked to take the allocated product according to the dose prescribed. In addition, participants will be asked to attend the study site at weeks 4, 8 and 12 for a body composition, satiety, dietary intake and tolerance assessment.
At the completion of the study (week 16), an assessment identical to what was undertaken at enrolment will be carried out.